GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.33
+0.28 (+0.70%)
At close: 4:02PM EDT

40.50 +0.16 (0.40%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close40.05
Open40.55
Bid39.90 x 900
Ask40.74 x 1000
Day's Range40.31 - 40.68
52 Week Range34.52 - 44.54
Volume3,240,702
Avg. Volume2,873,927
Market Cap99.1B
Beta0.70
PE Ratio (TTM)46.14
EPS (TTM)0.87
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.55 (6.53%)
Ex-Dividend Date2018-02-22
1y Target Est42.13
Trade prices are not sourced from all markets
  • MarketWatch3 hours ago

    Merck’s experimental and unlicensed Ebola vaccine is being used in latest outbreak

    The World Health Organization has started to vaccinate thousands of people considered at high risk of contacting the infectious and often-deadly disease Ebola in the Democratic Republic of Congo. The WHO said Monday it is working with NGOs and community leaders to administer an experimental vaccine that was studied in a trial in Guinea in 2015, but has not yet been used to contain a major outbreak. Most are in a remote town, but there are four confirmed cases in Mbandaka, the provincial capital which has a population of more than 1 million people.

  • Top Stock Reports for Cisco, Kraft Heinz & Sinopec
    Zacks6 hours ago

    Top Stock Reports for Cisco, Kraft Heinz & Sinopec

    Top Stock Reports for Cisco, Kraft Heinz & Sinopec

  • Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
    Zacks9 hours ago

    Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

    Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

  • Regulators flag possible birth defect link to GSK's HIV drug
    Reuters4 days ago

    Regulators flag possible birth defect link to GSK's HIV drug

    U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's (GSK.L) HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years. Friday's move by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) follows preliminary data from a study in Botswana which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

  • Reuters4 days ago

    Regulators flag possible birth defect link to GSK's HIV drug

    U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years. Friday's move by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) follows preliminary data from a study in Botswana which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

  • ACCESSWIRE4 days ago

    Free Stock Performance Review on Teva Pharma and Three Other Healthcare Sector

    WallStEquities.com has initiated research reports on the following Healthcare stocks: Novartis AG (NYSE: NVS), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), GlaxoSmithKline PLC (NYSE: GSK), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • GSK bets on lift from new lung drugs ahead of Advair's last gasp
    Reuters5 days ago

    GSK bets on lift from new lung drugs ahead of Advair's last gasp

    GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend. The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the ageing Advair inhaler, which could soon face generic competition in the United States. The market is also seeing intensified pricing pressure, raising doubts over the long-term profitability of newer drugs.

  • Reuters5 days ago

    GSK bets on lift from new lung drugs ahead of Advair's last gasp

    GlaxoSmithKline is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend. The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the ageing Advair inhaler, which could soon face generic competition in the United States. The market is also seeing intensified pricing pressure, raising doubts over the long-term profitability of newer drugs.

  • Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs
    Bloomberg5 days ago

    Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs

    GlaxoSmithKline Plc is cutting finance and accounting positions while bringing in people with cancer and science backgrounds as the U.K.’s biggest drug company shifts spending to develop its best new treatments. The new strategy has led to a “reasonable number” of job cuts, said Luke Miels, president of the London-based company’s global pharmaceutical division, declining to quantify them. Glaxo at the same time is increasing the number of medical science liaisons, specialists who establish relationships with top doctors, as well other roles, he said in an interview.

  • InvestorPlace5 days ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • Novartis Gains Ground, Completes the AveXis Acquisition
    Market Realist5 days ago

    Novartis Gains Ground, Completes the AveXis Acquisition

    Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.

  • GlobeNewswire6 days ago

    Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting

    PHILADELPHIA and OXFORD, U.K., May 16, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting ...

  • Analysts’ Recommendations for AstraZeneca as of May 15
    Market Realist6 days ago

    Analysts’ Recommendations for AstraZeneca as of May 15

    Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017. AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date.

  • AstraZeneca’s 1Q18 Estimates: CVMD Products
    Market Realist6 days ago

    AstraZeneca’s 1Q18 Estimates: CVMD Products

    AstraZeneca’s (AZN) Cardiovascular and Metabolic Disease (or CVMD) segment includes various products such as Brilinta, Farxiga, Bydureon, Byetta, Onglyza, and Symlin and legacy products such as Atacand, Crestor, and Seloken.

  • How Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18
    Market Realist6 days ago

    How Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18

    In 1Q18, Valeant Pharmaceuticals (VRX) Branded Rx segment generated revenues of $593.0 million, compared to $629.0 million in 1Q17. This reflected ~6.0% growth on a year-over-year (or YoY) basis and an ~1.0% decline quarter-over-quarter.

  • TheStreet.com6 days ago

    20 Top Stocks From Around the World With an Average 25% Upside Potential

    In this market, picking the right stocks is paramount. Here is a tidy list of top ideas from the strategy team at HSBC.

  • AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
    Market Realist7 days ago

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.

  • AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
    Zacks8 days ago

    AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

    AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

  • What’s behind Teva’s $706 Million Impairment Charges in 1Q18?
    Market Realist11 days ago

    What’s behind Teva’s $706 Million Impairment Charges in 1Q18?

    In 1Q18, Teva Pharmaceutical Industries (TEVA) recorded non-GAAP (generally accepted accounting principles) EPS (earnings per share) of $0.94 and net income of $954 million. The company made net non-GAAP adjustments of $101 million in 1Q18. Teva recorded $612 million of impairments in 1Q18 related to its US intangible assets due to the fair value revaluation of Actavis generics products, which were acquired in 2016, and goodwill impairment charges related to its Rimsa reporting unit due to the change in allocated net assets to the unit and the impact of the change in the weighted average cost of capital by ~0.5%.

  • Merck Focuses on Vaccines and Hospital Specialty Businesses in 2018
    Market Realist12 days ago

    Merck Focuses on Vaccines and Hospital Specialty Businesses in 2018

    In 1Q18, Merck’s (MRK) hospital specialty product, Bridion, reported global sales close to $204 million, which is a year-over-year (or YoY) rise of 38%. Since its launch in 2016, this product has managed to attain a significant share of the neuromuscular blockade reversal market. In 1Q18, Merck’s vaccines portfolio reported global sales close to $1.5 billion, which is a year-over-year (or YoY) rise of 4.3%.

  • Reuters13 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • Reuters13 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • How Merck’s Human Vaccines Business Performed in 1Q18
    Market Realist13 days ago

    How Merck’s Human Vaccines Business Performed in 1Q18

    In 1Q18, Merck’s (MRK) human vaccines business saw its total revenue grow 4.2% YoY (year-over-year) to $1.5 billion from $1.4 billion. Its Gardasil franchise includes vaccines used to prevent strains of sexually transmitted HPV (human papillomavirus) infections that cause genital warts and have been linked with cervical, vulvar, anal, penile, and vaginal cancer. 

  • GlobeNewswire13 days ago

    Adaptimmune Reports First Quarter 2018 Financial Results and Business Update

    -Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose-. -Updated MRCLS response data will be presented in an oral presentation at ASCO-. -Guidance confirmed, funded through to ...

  • Merck and AstraZeneca Announced EMA Approval for Lynparza
    Market Realist14 days ago

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.